An observational study in Cerebral Small Vessel Diseases, Cognitive Impairment and Diffusion Tensor Imaging, sponsored by Dongzhimen Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by Dongzhimen Hospital, Beijing · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Cerebral Small Vessel Diseases with a site in China — 32 open to participants now, 33 under way, 1 of them phase 3. Cerebral Small Vessel Diseases · China.
Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, this one is the 22nd largest by planned enrollment of the 22 observational ones that give a count, is one of 6 that started in 2025, is one of 22 observational ones, reaches primary completion later than 9 of the 32 other live ones, and was the 44th registered.
128 studies on the registry are indexed under Cerebral Small Vessel Diseases; 71 are open to participants now.
Browse Cerebral Small Vessel Diseases studies →32 of the 48 studies in Cerebral Small Vessel Diseases with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 30–80
Beijing Tiantan Hospital · Sites in China
Ages 45–80
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 30–79
Beijing Tiantan Hospital · Sites in China
Ages 50–75 · Healthy volunteers
Tongji Hospital · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Cerebral Small Vessel Diseases studies recruiting now, 26 (57%) set no upper age limit and 5 (11%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 260 across 56 observational studies indexed under Cerebral Small Vessel Diseases.
Median enrollment 105 across the 26 interventional studies, 749 across the 22 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 48 has an industry lead sponsor. The 10 most frequent:
Dongzhimen Hospital, Beijing is the lead sponsor of 45 studies on the registry; 19 are open to participants now.
Dongzhimen Hospital, Beijing has 2 studies filed under Cerebral Small Vessel Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Cerebral Small Vessel Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06674460Phase 3Peking Union Medical College HospitalTreatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease | 2027-10-01 |
| NCT07317557Jiangsu Province Nanjing Brain HospitalRemote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease | 2026-12-31 |
| NCT07271732Dongzhimen Hospital, BeijingSongling Xuemaikang Capsules for Cerebral Small Vessel Disease | 2026-12-31 |
| NCT05356104Chinese University of Hong KongGLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) | 2027-05 |
| NCT06512376Beijing Tiantan HospitalHereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort | 2027-07-19 |
Add all 8 to your calendar (.ics) → With an account.
Among the 48 studies in Cerebral Small Vessel Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The incidence of cerebral small vessel disease (CSVD) increases with age, affecting approximately 5% of individuals over 50 years old and nearly all individuals over 90 years old. CSVD is also the most important vascular factor contributing to cognitive decline, with 45% of dementia patients attributed to CSVD. Existing interventions are similar to secondary prevention strategies for cardiovascular and cerebrovascular diseases, and no specific therapies are currently available.
CSVD-related cognitive impairment (CSVDCI) predominantly involves attention, processing speed, and executive functions, with relatively preserved memory function, and may be accompanied by non-cognitive clinical manifestations such as gait disturbances, emotional and behavioral disorders, and bladder dysfunction. Although CSVDCI can be classified under vascular cognitive impairment (VCI), there are certain differences in its clinical manifestations.
In summary, it is necessary to develop more targeted treatments for CSVD. We attempt to establish a "symptom-tongue coating-gut microbiota-imaging" system to provide data support for the subsequent exploration of CSVD treatments based on traditional Chinese medicine (TCM) syndrome differentiation and treatment.
The study population mainly consisted of patients from the outpatient and inpatient departments of the Department of Neurology at Dongzhimen Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change from baseline in Montreal Cognitive Assessment (MoCA) at 6 month
Change from baseline in Montreal Cognitive Assessment (MoCA). Score range is 0-30. Higher score means good cognition.
Time frame: 6 months
Change from baseline in Mini-Mental State Examination (MMSE) at 6 month
Change from baseline in Mini-Mental State Examination (MMSE). Score range is 0-30. Higher score means good cognition.
Time frame: 6 months
Changes in whole-brain fiber connectivity at 6 month
Measure changes in whole-brain fiber connectivity on brain MRI diffusion tensor imaging (DTI).
Time frame: 6 months
Change from baseline in trail making test (TMT) at 6 month
Change from baseline in trail making test (TMT).TMT contains TMT-A and TMT-B. Both are related to age and education. The longer the duration of both tests, the poorer the ability to concentrate, process and perform.
Time frame: 6 months
Change from baseline in Tinetti Performance Oriented Mobility Assessment (POMA) at 6 month
Change from baseline in Tinetti Performance Oriented Mobility Assessment (POMA). Score range is 0-28. Lower score means higher risk of falling.
Time frame: 6 months
Change from baseline in instrumental activities of daily living (IADL) at 6 month
Change from baseline in instrumental activities of daily living (IADL). Score range is 0-24. Higher score means better daily living.
Time frame: 6 months
Change from baseline in Modified Rankin Scale (mRS) at 6 month
Change from baseline in Modified Rankin Scale (mRS).Score range is 0-6. Higher score means greater disability.
Time frame: 6 months
Change from baseline in the symptom at 6 month
Change from baseline in the symptom. The study plans to analyze whether there are statistically significant differences in the incidence of major symptoms before and after treatment. Patient-reported outcomes (PROs) will be used to record the degree of change in patients' symptoms from baseline (expressed as a percentage, with \>100% indicating symptom worsening and \<100% indicating symptom relief). Meanwhile, baseline and 6-month tongue coating photos will be preserved.
Time frame: 6 months
Change from baseline in gut microbiota at 6 month
Change from baseline in gut microbiota. Metagenomic sequencing technology will be applied to the analysis.
Time frame: 6 months
Numbers in new vascular events from baseline to 6 month
New vascular events include ischemic stroke, TIA, cerebral hemorrhage, MI, pulmonary embolism, thrombosis, peripheral arterial occlusion
Time frame: 6 months
Numbers in all-cause hospitalization from baseline to 6 month
Numbers in all-cause hospitalization
Time frame: 6 months
Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cerebral Small Vessel Diseases →
Dongzhimen Hospital, Beijing